StreetAlpha.app
Home › Stocks › JANX

Janux Therapeutics, Inc. (JANX)

Healthcare
$10.71
▼ −1.92%
LAST CLOSE · NOV 17

Janux Therapeutics develops immunotherapy drugs that direct the immune system's T cells to attack tumors and autoimmune disease. It last closed at $10.71 on Nov 17, down 1.92% on the day. The average 12-month price target from 4 analysts is $26.25 (+145.1% from the last close), with a high of $40.00 and a low of $15.00. Analyst consensus is Buy, based on the latest ratings from 4 firms (3 buy, 0 hold, 1 sell). In the past 30 days there were 1 dark pool print totaling $457K, the largest $457K.

AI Auto Pilots
Is JANX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$23.3M
+132.9% vs a year ago
Net income
−$99.8M
−428.7% margin
EPS (diluted)
−$1.59
Free cash flow
−$54.2M
−232.6% margin
Valuation
Market cap
$655.3M
61.2M shares
P/E
–
No P/E while losing money
Price to sales
28.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$41.8M
At Sep 30
Shareholder equity
$911.6M
Shares outstanding
61.2M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $3.6M$3.6MFY2021FY2022: $8.6M$8.6MFY2022FY2023: $8.1M$8.1MFY2023FY2024: $10.6M$10.6MFY2024FY2025: $10.0M$10.0MFY2025

From JANX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
4firms
3 Buy0 Hold1 Sell
Each firm's latest rating on JANX in the past 90 days
Average 12-month target
$26.25
▲ 145.1% upside

Based on 4 analysts who set a price target on JANX in the past 90 days. The average target is $26.25, with a high of $40.00 and a low of $15.00, compared with the last close of $10.71.

$8$20$31$42PAST 11 TRADING DAYS12-MONTH TARGETSHIGH $40AVG $26.25LOW $15Sep 23LAST CLOSE+12 MO$8$20$31$42PAST 11 DAYSTARGETSHIGH $40AVG $26.25LOW $15Sep 23LAST CLOSE+12 MO
Highest target$40.00
Average target$26.25
Lowest target$15.00
Latest rating changes
Truist SecuritiesTarget raised
Nov 6Buy$26 → $27
WedbushMaintained
Nov 6Buy$40
BarclaysTarget raised
Nov 6Sell$14 → $15
Wolfe ResearchUpgrade
Aug 24Buy$23
GuggenheimMaintained
Aug 7Buy$55
DateFirmActionRatingPrice target
Nov 6Truist SecuritiesTarget raisedBuy$26 → $27
Nov 6WedbushMaintainedBuy$40
Nov 6BarclaysTarget raisedSell$14 → $15
Aug 24Wolfe ResearchUpgradeBuy$23
Aug 7GuggenheimMaintainedBuy$55
Loading…

Technical Analysis

JANX · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 43% below its 20 day and 53% below its 50 day average. It is 43% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 27), oversold. The nearest support is the 52 week low at $10.53, and the nearest resistance the Pivot at $10.72.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 10.1%/day
Key levels
$35.3452 week high+230.0%
$16.55100 day average+54.5%
$16.4350 day average+53.4%
$15.3420 day average+43.2%
$15.33200 day average+43.1%
$14.03Swing high (Jun 10)+31.0%
$10.91Pivot R1+1.9%
$10.72Pivot+0.1%
$10.71Last close
$10.5352 week low−1.7%
$10.52Pivot S1−1.8%
Indicators
RSI (14)27.12Oversold below 30Oversold
MACD-1.64Below its signal lineBearish
Stochastic2.5Near the bottom of its rangeOversold
ADX (14)29.3Trending down
Williams %R-97.8Oversold below −80, overbought above −20Oversold
CCI (20)-128.6Oversold below −100, overbought above 100Oversold
Rate of change−39.9%Change over 10 sessionsBearish
ATR (14)$1.08Typical daily range, 10.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for JANX

What happened before

See how JANX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow JANX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How JANX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in JANX in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$457K
Largest print
$457K
Loading…

JANX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲123 buying vs 79 selling
  • ●Held by funds -0.5 pts
  • ▲Funds holding +5
  • ▼Superinvestors: 0 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding204199+2.5%
In funds' top 10110.0%
Held by funds100.2%100.7%−0.5 pts
New / increased32 / 9138 / 84+0.8%
Reduced / sold out52 / 2746 / 31+2.6%
Put/call ratio0.720.23+209.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See JANX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether JANX is in one of them and how their past JANX trades turned out.

JANX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered JANX in an article yet. Here's the latest on the wider market.

About Janux Therapeutics

Janux Therapeutics is a biopharmaceutical company based in San Diego, California. It develops immunotherapy drugs that direct the body's T cells to attack tumors, and it is also developing treatments for autoimmune diseases. Its lead candidates are in clinical trials for prostate cancer and other solid tumors. The company's drug candidates are aimed at cancer patients and people living with autoimmune conditions.

Headquarters
San Diego, CA